Phenotypic plasticity in vascular smooth muscle cells (VSMC) is necessary for vessel maintenance, repair and adaptation to vascular changes associated with aging. De-differentiated VSMC contribute to pathologies including atherosclerosis and intimal hyperplasia. As resveratrol has been reported to have cardio- protective effects, we investigated its role in VSMC phenotypic modulation. We demonstrated the novel finding that resveratrol promoted VSMC differentiation as measured by contractile protein expression, contractile morphology and contraction in collagen gels. Resveratrol induced VSMC differentiation through stimulation of SirT1 and AMPK. We made the novel finding that low or high dose resveratrol had an initially different mechanism on induction of differentiation. We found that low dose resveratrol stimulated differentiation through SirT1-mediated activation of AKT, whereas high dose resveratrol stimulated differentiation through AMPK-mediated inhibition of the mTORC1 pathway, allowing activation of AKT. The health effects of resveratrol in cardiovascular diseases, cancer and longevity are an area of active research. We have demonstrated a supplemental avenue where-by resveratrol may promote health by maintaining and enhancing plasticity of the vasculature.
References
[1]
Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767–801.
[2]
Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB (2012) The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 95: 194–204.
[3]
Martin K, Merenick B, Ding M, Fetalvero K, Rzucidlo E, et al. (2007) Rapamycin promotes vascular smooth muscle cell differentation through insulin receptor substrate-1/phosphatifylinositol 3-kinase/Akt2 feedback signaling. Journal of Biological Chemistry 282: 36112–36120.
[4]
Ding M, Xie Y, Wagner R, Jin Y, Carrao A, et al. (2011) Adiponectin induces vascular smooth muscle cell differentation via repression of mammalian target of rapamycin complex 1 and foxo4. Arteriosclerosis, Thrombosis, Vascular Biology 31.
[5]
Chang Z (2010) PKB/Akt signaling in cardiac development and disease. frontiers in bioscience.
[6]
Catalgol B, Batirel S, Taga Y, Ozer NK (2012) Resveratrol: French paradox revisited. Front Pharmacol 3: 141.
[7]
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating sirt1 and pgc1alpha. Cell 127: 1109–1122.
[8]
Haigis M, Sinclair D (2010) Mammalian sirtuins: biological insight and disese relevance. Annu Rev Pathol Mech Dis 5: 253–295.
[9]
Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056–1060.
[10]
Klar AJ, Fogel S, Macleod K (1979) MAR1-a Regulator of the HMa and HMalpha Loci in SACCHAROMYCES CEREVISIAE. Genetics 93: 37–50.
[11]
Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 11: 443–461.
[12]
Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of sirtuins. Annu Rev Biochem 75: 435–465.
[13]
Westphal C, Dipp M, Guarente L (2007) A theraputic role for sirtuins in diseases of aging? Trends in biochemical sciences 32.
[14]
Li X, Tsai P, Wieder ED, Kribben A, Van Putten V, et al. (1994) Vascular smooth muscle cells grown on Matrigel. A model of the contractile phenotype with decreased activation of mitogen-activated protein kinase. J Biol Chem 269: 19653–19658.
[15]
Murray T, Marshall B, Macarak E (1990) Contraction of vascular smooth mucle in cell culture. Journal of cellular physiology 143: 26–38.
[16]
Yang L, Dan H, Sun M, Liu Q, Sun X, et al. (2004) Akt/Protein kinase b signaling inhibitor-2, a selective small molecule inhibitor of akt signaling with anittumor activity in cancer cells overexpressing akt. cancer research 64: 4394–4399.
[17]
Ruderman N, Xu J, Nelson L, Cacicedo J, Saha A, et al. (2010) AMPK and SIRT1: a long standing partership? Am J Physiol Endocrinol Metab 298.
[18]
Borradaile NM, Pickering JG (2009) NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des 15: 110–117.
[19]
Fullerton M, Steinberg G (2010) SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivtiy by resveratrol. Diabetes 59.
[20]
Lan F, Cacicedo JM, Ruderman N, Ido Y (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283: 27628–27635.
[21]
Sundaresan N, Pillai V (2011) The Deactylase SIRT1 Promotes membrane localization and activation of AKT and PDK1 during tumorigenesis and cardiac hypertrophy. Science Signaling 4.
[22]
Ghosh HS, McBurney M, Robbins PD (2010) SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5: e9199.
[23]
Baur J, Sinclair D (2006) Theraputic potential of resveratrol: the in vivo evidence. Nature reviews 5.
